Clofabosin: Difference between revisions
m →Todo |
mNo edit summary |
||
| Line 388: | Line 388: | ||
Yes-no questions are formed by adding the question particle ''pegol'' to the subjunctive: ''Zenazumab pegol?'' (Did he go?). However, colloquial speech often shortens this to ''-mapel'' or even ''-mpel''. "What" questions do ''not'' use this ending: ''cesin gliserotin(avir)?'' = what language is this? | Yes-no questions are formed by adding the question particle ''pegol'' to the subjunctive: ''Zenazumab pegol?'' (Did he go?). However, colloquial speech often shortens this to ''-mapel'' or even ''-mpel''. "What" questions do ''not'' use this ending: ''cesin gliserotin(avir)?'' = what language is this? | ||
The negative uses the ''- | The negative uses the ''-fo-'' marker after the verb stem: ''sabafovir'' 'he does not write' (usually pronounced [sabafoiɾ] or [sabafoːr]). For subjunctive forms, the negative marker is ''-tu(m)-'': ''Sabatumab!'', ''Sabatumumab!'' or ''Sabatumomab!'' means 'Don't write!' | ||
*'can' (ability) uses ''-tecan'' (inflected as if it were ''-tecavir''; the attributive is ''-taxel'') | *'can' (ability) uses ''-tecan'' (inflected as if it were ''-tecavir''; the attributive is ''-taxel'') | ||
| Line 438: | Line 438: | ||
|- | |- | ||
! Past | ! Past | ||
| ''-nazole'' || ''- | | ''-nazole'' || ''-fozole'' || ''-nazumab'' || ''-tuzumab'' | ||
|- | |- | ||
! Present | ! Present | ||
| ''-navir'' || ''- | | ''-navir'' || ''-fovir'' || ''-numab'' || ''-tumab'' | ||
|- | |- | ||
! Timeless | ! Timeless | ||
| ''-natinib'' || ''- | | ''-natinib'' || ''-fotinib'' || ''-navetmab'' || ''-tuvetmab'' | ||
|- | |- | ||
! Future | ! Future | ||
| ''-nercept'', ''-navircept'' || ''- | | ''-nercept'', ''-navircept'' || ''-focept'', ''-fovircept'' || ''-naximab'' || ''-tuximab'' | ||
|} | |} | ||